<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694408</url>
  </required_header>
  <id_info>
    <org_study_id>SFPT/OL</org_study_id>
    <nct_id>NCT00694408</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of Pediatric Liver Transplantation Without Steroids</brief_title>
  <official_title>A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birmingham Women's and Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Birmingham Women's and Children's NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      The overall objective is to investigate whether a steroid free immunosuppressive regimen is
      as safe and effective as a steroid containing regimen following pediatric liver
      transplantation and whether it promotes tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3.2 Research question

      Is it possible to avoid the use of corticosteroids in pediatric liver transplantation?

      3.3 Trial objectives

      This will be a pilot study to

      i) investigate to what degree a steroid free immunosuppressive regimen is as safe and
      effective as a steroid containing regimen following pediatric liver transplantation

      ii) investigate the effect of a steroid free immunosuppressive regimen on lymphocyte function
      and donor-specific immune responsiveness following pediatric liver transplantation

      iii) investigate the effect of a steroid free immunosuppressive regimen on expression of
      tissue markers of tolerance following pediatric liver transplantation

      It is hoped that this pilot study will be used to develop a definitive multicentre study of a
      steroid free regimen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to withdrawal from market of Daclizumab
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: The development of histologically proven acute rejection. (within 12 months</measure>
    <time_frame>12m</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The development of steroid resistant acute rejection 12 months. The expression of tissue and circulating markers of immune tolerance in first year post transplant The incidence of infection in the first year post transplant</measure>
    <time_frame>12m</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Steroid immunosuppressive regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid free immunosuppressive regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyl prednisolone, hydrocortisone, prednisolone</intervention_name>
    <description>Will be specific dependant on weight of patients</description>
    <arm_group_label>Steroid immunosuppressive regimen</arm_group_label>
    <other_name>Methylprednisolone;Hydrocortisone;Prednisolone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No steroids</intervention_name>
    <description>Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol</description>
    <arm_group_label>Steroid free immunosuppressive regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children undergoing primary isolated hepatic transplantation.

          -  Age &lt;=18 years

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Children undergoing retransplantation.

          -  Transplantation for Intestinal failure associated liver disease.

          -  Multi-organ transplantation.

          -  Transplantation for autoimmune liver disease.

          -  Transplantation for extra hepatic malignancy.

          -  Pre-existing need for oral steroids, or high dose inhaled steroids sufficient to
             require a steroid warning card.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick McKiernan, MRCP FRCPCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Birmingham Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation. 2003 Nov 15;76(9):1331-9.</citation>
    <PMID>14627912</PMID>
  </reference>
  <reference>
    <citation>Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol. 2005 Mar;20(3):418-26. Epub 2005 Feb 3. Review.</citation>
    <PMID>15690189</PMID>
  </reference>
  <reference>
    <citation>Leonard H, Hornung T, Parry G, Dark JH. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant. 2003 Feb;7(1):59-63.</citation>
    <PMID>12581330</PMID>
  </reference>
  <reference>
    <citation>Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest. 2004 Nov;114(10):1398-403. Review.</citation>
    <PMID>15545987</PMID>
  </reference>
  <reference>
    <citation>Yoshizawa A, Ito A, Li Y, Koshiba T, Sakaguchi S, Wood KJ, Tanaka K. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc. 2005 Jan-Feb;37(1):37-9.</citation>
    <PMID>15808539</PMID>
  </reference>
  <reference>
    <citation>Hathaway M, Adams DH. Demonstration that donor-specific nonresponsiveness in human liver allograft recipients is both rare and transient. Transplantation. 2004 Apr 27;77(8):1246-52.</citation>
    <PMID>15114093</PMID>
  </reference>
  <reference>
    <citation>Arora-Gupta N, Davies P, McKiernan P, Kelly DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant. 2004 Apr;8(2):145-50.</citation>
    <PMID>15049794</PMID>
  </reference>
  <reference>
    <citation>Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation. 2005 Jun 15;79(11):1575-80.</citation>
    <PMID>15940048</PMID>
  </reference>
  <reference>
    <citation>Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004 Sep 18-24;364(9439):1054-61.</citation>
    <PMID>15380964</PMID>
  </reference>
  <reference>
    <citation>Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children. Lancet. 2003 Dec 20;362(9401):2068-70.</citation>
    <PMID>14697809</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2008</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End stage liver disease</keyword>
  <keyword>Paediatric liver transplantation</keyword>
  <keyword>Steroid free immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

